The 200 Most Cited Articles in EGRF Mutant Non-small Cell Lung Cancer Bibliometric Analysis
Mehmet Uzun11Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaras, Türkiye
Objectives: We analyzed the top 200 most cited EGFR mutant metastatic non-small cell lung cancer (NSCLC) articles. We aimed to highlight advancements and provide easy access to researchers in this dynamic field. Methods: This research was conducted using the Web of Science (WoS) Core Collection database. The following keywords were used: "lung cancer" and (treat* or medic* or remedy or cure or therapy) and (mutant or mutation) and (egfr or “epidermal growth factor receptor”). The top 200 most cited articles were analyzed by topic, journal, author, year, country, keywords, and average citations per article. Results: A total of 16.165 eligible articles were identified, and the top 200 most cited articles in the EGFR-mutant NSCLC field were selected. The average number of citations for these articles was 724.95. The most cited article (number of citations: 8,899) was by Chmielecki et al. The Journal of Clinical Oncology contributed the most to the top 200 list with 50 articles, while the most cited article was published in Science Translational Medicine. Conclusion: The top 200 articles in our study not only reflect the most impactful studies in the EGFR-mutant NSCLC field but also highlight the most productive authors, journals, and countries contributing to this list. Keywords: EGFR, Lung Cancer, NSCLC, Erlotinib, Bibliometric Analysis
Cite This Article
Uzun M. The 200 Most Cited Articles in EGRF Mutant Non-small Cell Lung Cancer Bibliometric Analysis. EJMI. 2024; 8(4): 245-250
Corresponding Author: Mehmet Uzun